SAN DIEGO, CA and EDMONTON, CANADA, July 19, 2012 — Conatus Pharmaceuticals Inc. and the University of Alberta announced today the treatment of the first patient in an investigator-initiated islet cell transplant Phase I/II trial of emricasan (IDN-6556), a pan-caspase inhibitor. The objective of the trial is to determine safety, achievement and maintenance of insulin […]
Blog: Press, Pharma News, Drug Reviews
SAN DIEGO, July 17, 2012 — Conatus Pharmaceuticals Inc. announced today the appointment of Daniel Ripley as Head of Corporate Development, effective immediately. Mr. Ripley will lead licensing, partnering initiatives, intellectual property analysis and act as the internal coordinator of the emricasan commercialization strategy development. “Dan brings experience in both in-licensing and out-licensing of commercial […]
SAN DIEGO, June 11, 2008 — Conatus Pharmaceuticals Inc. announced today that an independent investigator at the Mayo Clinic reported that treatment with CTS-1027 in a preclinical model of liver disease resulted in an attenuation of hepatic fibrosis. These data were presented at the May 2008 Digestive Disease Week (DDW) meeting held in San Diego, […]
SAN DIEGO, May23, 2007 — Conatus Pharmaceuticals Inc. today announced the election of Harold Van Wart, Ph.D., to the Companys Board of Directors. Dr. Van Wart currently serves as President and Chief Executive Officer of Metabolex, Inc., a privately-held life science company in Hayward, CA. He joined Metabolex in 2000 as Senior Vice President, Research […]
SAN DIEGO, April 12, 2011 — Conatus Pharmaceuticals Inc. today announced an additional $7.5 million investment by MPM Capital of South San Francisco, CA. The Series B Preferred Stock financing is now closed with a total of $32.5 million of capital raised. The first closing was completed in early February, 2011. Jim Scopa from MPM […]
SAN DIEGO, March 31, 2011 — Conatus Pharmaceuticals Inc. announced today 24-week interim results from a clinical trial with CTS-1027 in combination with Peginterferon Alpha-2a (Pegasys®) and ribavirin (Copegus®) in a treatment experienced, hepatitis C virus (HCV) null-responder patient population. Null-responder patients are the most difficult to treat patient population and are clinically defined as […]
SAN DIEGO, March 25, 2008 — Conatus Pharmaceuticals Inc. today announced the appointment of Anthony “Tony” W. Fox as part-time Chief Medical Officer to oversee the recently initiated Phase 2 clinical trial of CTS-1027 in Hepatitis C virus-infected patients as well as assisting in the development of the longer-term clinical development plans. Tony is a […]
SAN DIEGO, March 11, 2011 — Conatus Pharmaceuticals Inc. today announced the acceptance of two poster presentations of Phase 2 clinical trial data of CTS–1027 for the treatment of hepatitis C virus–infected patients at the 46th annual meeting of the European Association for the Study of the Liver (EASL) to be held in Berlin, Germany, […]
SAN DIEGO, January 28, 2010 — Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys®) and ribavirin (Copegus®) in refractory HCV patients. Antiviral activity, safety and tolerability of the triple combination will be assessed after up to 48 weeks of therapy. “There is […]
SAN DIEGO, December 20, 2007 — Conatus Pharmaceuticals Inc. today announced the initiation of a clinical trial with a novel drug candidate for the treatment of liver disease associated with Hepatitis C Virus (HCV) infection in patients who have failed the approved standard of care treatments. The oral, small molecule drug candidate, CTS-1027, is being […]